Method: The Malmö Diet and Cancer cohort (n=28098, age 45-73 years, 61% women) was established between 1991 and
Results: A total of 465 incident cases of knee OA and 554 of hip OA occurred during the follow-up. After adjustments for risk factors, high dietary intake of Vitamin C and selenium was significantly associated with incidence of hip OA [hazards ratio: 1.45 (95%CI:1.09-1.9) and 1.32 (95%CI: 1.01-1.7), respectively, for the highest versus lowest quintile of the antioxidant]. When consumption of antioxidant supplements was taken into account, high selenium intake was significantly associated with incidence of both hip and knee OA. There was no evidence of any protective effect for any of the antioxidants.
Table 3. Intake of four antioxidants in relation to knee or hip OA during follow-up.
| Knee OA |
|
| Hip OA |
|
|
| yes | no | P | yes | No | P |
| N | 465 | 27196 |
| 544 | 27055 |
|
| Beta-carotene | 4.1+3.6 (3.2) | 3.8+3.4 (2.8) | 0.03 | 4.0+3.1 (3.2) | 3.8+3.4 (2.8) | 0.11 |
| Beta-carotene* | 4.2+3.6 (3.2) | 3.9+3.9 (2.8) | 0.05 | 4.1+3.4 (3.2) | 3.9+3.9 (2.8) | 0.10 |
| Vitamin E | 10.4+4.2 (9.6) | 10.6+4.3 (9.8) | 0.26 | 10.5+4.0 (9.5) | 10.6+4.3 (9.8) | 0.94 |
| Vitamin E* | 17.1+27 (10.9) | 16.1+28 (11.1) | 0.14 | 15.4+16 (11) | 16.1+28 (11) | 0.90 |
| Vitamin C | 114+62 (103) | 110+62 (98) | 0.01 | 116+59 (105) | 110+62 (98) | 0.01 |
| Vitamin C* | 174+243 (124) | 175+267 (116) | 0.24 | 166+194 (120) | 176+268 (116) | 0.39 |
| Selenium | 40.3+14 (38) | 39.3+14 (37) | 0.007 | 41.7+16 (39) | 39.2+14 (37) | <0.001 |
| Selenium* | 49.1+27 (41) | 46.9+26 (40) | 0.02 | 51.8+29 (43) | 46.8+26 (40) | <0.001 |
Values are crude mean±SD (median). Log transformed values used for calculation of p-values, adjusted for age, sex, method, log energy, season
Conclusion: In this population-based study, there was no evidence of a protective effect of antioxidants against severe knee or hip OA leading to arthroplasty. The association between high intake of Vitamin C and selenium and incidence of severe OA needs to be confirmed by other prospective studies with data on diet and intake of supplements.
Disclosure: G. Engström, AstraZeneca, 3 ; M. Gerhardsson de Verdier, AstraZeneca, 3 ; P. M. Nilsson, None; E. Wirfält, None; C. Mellström, AstraZeneca, 3 ; J. Rollof, AstraZeneca, 3 ; S. Lohmander, AstraZeneca, 2 .
![[Visit Client Website]](/img/acr/banner_2009.gif)
Search
Print Page
Browse by Day: